F

Fortis Life Sciences

Tech-driven financial planning and investment services

Pardot Specialist

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Waltham, MA, USA
Remote
Growth & MarketingGrowth Marketing

About the job

Requirements
  • At least 3 years of Salesforce experience.
  • At least 3 years of Salesforce Pardot experience.
  • Solid knowledge of HTML and CSS coding for email.
  • A BA or BS degree is required.
  • Ability to work independently and as part of a cross-functional team.
  • Demonstrated written, verbal, and interpersonal communication skills.
  • Ability to adapt in a fast-paced environment where strategies or campaigns can shift with business needs.
  • Strong analytical skills and ability to give direction, solve problems, take on new challenges, and maintain attention to detail.
  • Ability to manage simultaneous campaigns while maintaining organization, accuracy, and attention to detail.
  • Hands-on experience building B2B marketing programs using Pardot to drive qualified leads into the sales funnel.
  • Familiarity with Pardot lead qualification processes, including grading and scoring.
  • Knowledge of account-based marketing.
  • Knowledge of configuring and managing Salesforce and Pardot connectors.
  • Knowledge of best practices for administering the Pardot ecosystem.
Responsibilities
  • Oversee and execute complex automated marketing programs in Pardot, collaborating with the Programs Management Team and Product Managers to maximize program effectiveness.
  • Administer marketing automation, including creating, scheduling, and reporting on emails, forms, landing pages, and campaigns; creating and segmenting lists; building nurture programs; supporting and troubleshooting CRM integrations and marketing technology connectors; and managing users and assets.
  • Create user personas and segmentation rules to develop content strategies and customer journeys.
  • Optimize the lead-scoring model and manage processes to improve lead quality and volume.
  • Build campaign workflows for drip campaigns, including targeting and timing logic, conditional scenarios, behavior-based workflows, calls to action, sender logic, and automated tasks.
  • Use progressive profiling to improve conversions.
  • Troubleshoot reported errors to ensure campaigns run as designed, opt-outs are processed successfully, and correct variable fields are used for personalization.
  • Own and maintain marketing-specific dashboards in business intelligence and/or CRM software.
  • Establish, document, and maintain scalable best-practice processes for campaign and lead management.
  • Provide stakeholders with insights into campaign performance, demand-generation metrics, and key performance indicators using Pardot, Salesforce, and/or other business intelligence platforms.
  • Collaborate with the Salesforce Administrator on data deduplication and cleanup procedures, including data migrations and bulk data uploads.
  • Work alongside the Senior Digital Marketing Leader as a subject matter expert and administrator of the B2B marketing automation platform.
Desired Qualifications
  • Pardot certification.
  • Experience managing paid media platforms focused on lead generation.

About the company

Fortis Life Sciences is a technology-driven financial services company that helps people make better financial decisions. Its flagship offering is a personalized financial planning tool that creates tailored plans for budgeting, saving, investing, and other financial needs, using data-driven insights to generate customized recommendations. Beyond planning, the company provides financial literacy education and a range of investment products, including mutual funds and ETFs, to broaden access to investment opportunities. The business differentiates itself by focusing on accessibility, transparency, and affordability, delivering an integrated suite that combines planning tools, educational resources, and investment options in one place. Fortis Life Sciences aims to empower individuals to manage their money more effectively and reach their financial goals by making financial services easier to understand and use.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Boston, Massachusetts

Founded

2020

Get referred to Fortis Life Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 12, 2026 Deliver Biosciences win validates AbNano for translational drug-delivery programs.
  • May 28, 2026 NK-cell library targets CAR-NK and complex receptor discovery demand.
  • 26 active locations and multiple manufacturing sites expand cross-sell into diagnostics and biologics.

What critics are saying

  • Fortis still lacks disclosed funding and profitability, limiting acquisition and expansion flexibility.
  • Heavy integration across six brands risks duplicate systems, slower launches, and margin dilution.
  • Bigger reagent rivals can undercut AbNano and diagnostics; weak differentiation kills standalone demand.

What makes Fortis Life Sciences unique

  • Fortis combines Abcore, Bethyl, IPOC, nanoComposix, and Vector Biolabs into one platform.
  • May 28, 2026 AbNano Anti-NK library adds differentiated single-domain discovery capabilities.
  • Three ISO 13485 GMP sites support diagnostics, antibodies, and viral-vector commercialization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Disability Insurance
  • Life Insurance
  • 401(k) Retirement Plan

Company News

GlobeNewswire
May 12th, 2026
Fortis Life Sciences awards 2026 AbNano(R) VHH Discovery grant to Deliver Biosciences for targeted drug delivery research.

Fortis Life Sciences awards 2026 AbNano(R) VHH Discovery grant to Deliver Biosciences for targeted drug delivery research. Grant program expands access to advanced single-domain antibody technologies to support the research and development of next-generation therapies. BOSTON and LONDON, May 12, 2026 (GLOBE NEWSWIRE) - Fortis Life Sciences and Deliver Biosciences today announced that Fortis named Deliver Biosciences as the inaugural recipient of the 2026 Fortis Grant Series. The Fortis Grant featured AbNano VHH Discovery services as an initiative to create greater opportunities for organizations using new technologies to develop high-potential therapeutic programs. "We look forward to applying AbNano(R) capabilities to advance our work in in vivo CAR-T and gene therapy." - George Tetley Many serious diseases remain difficult to treat because the biological targets that drive them are often difficult to access with conventional antibodies. Large antibody formats can struggle to penetrate dense tissues such as solid tumors, limiting their therapeutic potential. VHH antibodies offer a promising alternative. Their smaller size, low immunogenicity, and stability can help them move through tissue more effectively, bind with precision, and support new classes of treatments. For researchers and drug developers, this enables faster development timelines, reduced biological barriers, enhanced targeting precision, and new opportunities across cancer, autoimmune disease, gene therapy, and targeted drug delivery. The Fortis Grant Series gives academic institutions, nonprofit organizations, biotechnology and pharmaceutical companies access to antibody discovery services that are often too costly or specialized to build internally. "Many of the next breakthroughs in medicine will come from scientists solving difficult biological problems in areas such as cancer, immune disease and gene therapy," said Chris Woodward, senior director of sales and marketing, antibody solutions, at Fortis Life Sciences. "The grant series accelerates that work by providing the discovery expertise and antibody technologies needed to turn promising science into therapeutic candidates." Fortis reviewed applications from organizations worldwide and evaluated proposals based on scientific merit, innovation, feasibility, and potential downstream impact. The submission from George Tetley and Deliver Biosciences was selected as the winner. Deliver Biosciences is developing targeted drug delivery technologies designed to bring therapies directly to intended cells to support future therapeutic strategies for diseases including HIV, sickle cell disease, and neurodegenerative disorders. "Access to advanced discovery infrastructure can significantly influence what an emerging biotechnology company can pursue and how efficiently it can generate data, evaluate targets, and prioritize development paths," said George Tetley, Ph.D., co-founder and chief scientific officer of Deliver Biosciences. "We look forward to applying AbNano capabilities to advance our work in in vivo CAR-T and gene therapy, with the goal of bringing new therapies to patients." About Fortis Life Sciences Established in 2020, Fortis Life Sciences integrates specialized life science companies including Abcore, Arista Biologicals, Bethyl Laboratories, Empirical Bioscience, IPOC, nanoComposix and Vector Biolabs to help organizations move from discovery to commercialization with greater speed, continuity and control. By providing premium products, custom services and deep technical expertise, Fortis helps partners create, validate and manufacture proprietary solutions for complex scientific and operational requirements. Fortis serves organizations worldwide through a growing global footprint, including multiple cGMP-compliant manufacturing sites certified to ISO 13485. Learn more at fortislife.com About Deliver Biosciences Deliver Biosciences develops targeted nanoparticle delivery vectors designed to transport a broad range of therapeutic payloads safely and efficiently to specific cells in vivo, with a lead candidate progressing towards clinic for in vivo CAR-T therapy. Its platform is built to support cell reprogramming and next-generation modalities including gene editing, immunotherapy, and precision medicine. The company's focus spans cancer immunotherapy, with long-term applications in autoimmune, neurodegenerative, and cardiovascular diseases where significant unmet medical needs remain. Learn more at deliverbio.com Media Contact: Nick Bartosik Marketing Specialist Fortis Life Sciences [email protected]

Astraea Bio
Aug 19th, 2025
Astraea Bio Proudly Announces Collaboration with Fortis Life Sciences

Astraea Bio is proud to announce its collaboration with Fortis Life Sciences, a partnership that represents a significant step forward in its mission to advance the field of spatial biology and multi-omics research.

Industry Today
Mar 27th, 2025
Lateral Flow Assays Market Dynamics and Regional Growth Analysis 2030 - Exclusive Research Report by Arizton

Fortis Life Sciences, a prominent market player, has introduced advanced LFA kits incorporating Au NPs, delivering up to 20 times greater sensitivity compared to traditional gold colloids.

Securities.io
Dec 7th, 2023
Finding New Utility For Gold As A Generation Moves Away From Its “Store Of Value”

The history of gold as a store of value goes back many centuries, laying the groundwork for its pivotal role in global economics. By the late 19th Century, several major global economies followed the Gold Standard, wherein many of the major currencies worldwide were fixed to gold at a set price per ounce.The World Gold Council carried out extensive studies on the use of gold over the years. In their findings, it has designated the period between 1660 and 1819 as the rise of the gold standard, marking a significant evolution in its usage. Subsequently, the period between 1820 and 1930 was considered the heyday of the gold standard, reflecting its peak influence. Following this era, the period spanning from 1931 to 1999 is what the World Gold Council terms “After the Gold Standard,” indicating a shift in the global economic landscape.Click here for the list of the ten best gold stocks to invest in.How the Days of the ‘Gold Standard' Faded AwayIn 1944, during the end of the WWII days, the United States hosted the Bretton Woods conference. This conference dealt with the need for a new international system replacing the Gold System and positioning the dollar at the center since the United States dominated the global economic and political scene

Business Wire
Jul 13th, 2023
Fortis Life Sciences acquires International Point of Care

Fortis Life Sciences, LLC (“Fortis”) has acquired Toronto-based International Point of Care, Inc. (“IPOC”). IPOC develops and manufactures key compone